TNF and rheumatoid arthritis: In a phase IIb study, the primary endpoint was met; patients with active RA who had previously failed TNF inhibitor therapy demonstrated a significant decrease in DAS28-CRP at week 12 for all doses (60 mg, 120 mg, and 240 mg) administrated every four or every two weeks with results comparable to tocilizumab31.